ArticleThe Canadian journal of cardiology2024
Kawasaki Disease in the Time of COVID-19 and MIS-C: The International Kawasaki Disease Registry.
Article in The Canadian journal of cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Importance of Fostering International Collaboration for Optimal Outcomes of Kawasaki Disease Worldwide: A Science Advisory From the American Heart Association.Journal of the American Heart Association · 2026Guideline
- Systemic Arterial Aneurysms in Kawasaki Disease: An Important Evidence Gap.Pediatric cardiology · 2026Pooled it
- Current Prognostic Models Fail to Reliably Distinguish Kawasaki Disease From Pediatric Multisystem Inflammatory Syndrome Temporally Associated With COVID-19.The Pediatric infectious disease journal · 2026Article
- Gastrointestinal Symptoms in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children.Pediatric cardiology · 2026Article
- Incomplete Kawasaki Disease Versus Non-severe Multisystem Inflammatory Syndrome in Children: Distinguishing Features from Contemporaneous Patients.Pediatric cardiology · 2026Article
- Kawasaki Disease-Related Mortality in Arab Countries: A Multinational Physician Survey from the Kawasaki Disease Arab Initiative (Kawarabi).Pediatric cardiology · 2026Article
- Did the COVID-19 pandemic change the Kawasaki disease phenotype? Observations from the International Kawasaki Disease Registry.Pediatric cardiology · 2026Article
- Review
- Kawasaki disease in the pre- and post-COVID-19 era: shifts in patterns and outcomes from a multi-center study.European journal of pediatrics · 2025Article
- Spectrum of Coronary Artery Involvement With Multisystem Inflammatory Syndrome in Children Versus Kawasaki Disease.Journal of the American Heart Association · 2025Article
- Cardiovascular post-acute sequelae of SARS-CoV-2 in children and adolescents: cohort study using electronic health records.Nature communications · 2025Article
- Pharmacoeconomic Analysis and Considerations for the Management of Kawasaki Disease in the Arab Countries-A Multinational, Multi-Institutional Project of the Kawasaki Disease Arab Initiative (Kawarabi) (A Project Methodology Paper).Turkish archives of pediatrics · 2025Article
- Coronary Arteries Lesions in Kawasaki Disease: Risk Factors in an Italian Cohort.Biomedicines · 2024Article
- Clinical Significance of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Pediatric Patients: Insights into Their Utility in the Presence or Absence of Pre-Existing Heart Conditions.International journal of molecular sciences · 2024Review
- A Tale of a Trail on How It Takes 5 Days of Kawasaki Disease to Initiate Coronary Artery Injury and Change the Lives of Children.Turkish archives of pediatrics · 2024Article
- MIS-C Overlap, Not Prior COVID-19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
- Commented on by
Authors and funding
24 authors at 20 institutions in 4 countries.
Funding
Abstract
backgroundPatients with multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease (KD) have overlapping clinical features. We compared demographics, clinical presentation, management, and outcomes of patients according to evidence of previous SARS-CoV-2 infection.
methodsThe International Kawasaki Disease Registry (IKDR) enrolled KD and MIS-C patients from sites in North, Central, and South America, Europe, Asia, and the Middle East. Evidence of previous infection was defined as: Positive (household contact or positive polymerase chain reaction [PCR]/serology), Possible (suggestive clinical features of MIS-C and/or KD with negative PCR or serology but not both), Negative (negative PCR and serology and no known exposure), and Unknown (incomplete testing and no known exposure).
resultsOf 2345 enrolled patients SARS-CoV-2 status was Positive for 1541 (66%) patients, Possible for 89 (4%), Negative for 404 (17%) and Unknown for 311 (13%). Clinical outcomes varied significantly among the groups, with more patients in the Positive/Possible groups presenting with shock, having admission to intensive care, receiving inotropic support, and having longer hospital stays. Regarding cardiac abnormalities, patients in the Positive/Possible groups had a higher prevalence of left ventricular dysfunction, and patients in the Negative and Unknown groups had more severe coronary artery abnormalities.
conclusionsThere appears to be a spectrum of clinical features from MIS-C to KD with a great deal of heterogeneity, and one primary differentiating factor is evidence for previous acute SARS-CoV-2 infection/exposure. SARS-CoV-2 Positive/Possible patients had more severe presentations and required more intensive management, with a greater likelihood of ventricular dysfunction but less severe coronary artery adverse outcomes, in keeping with MIS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.